Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Clinical Trials Using Gemtuzumab Ozogamicin

Review the clinical trials studying gemtuzumab ozogamicin on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-11 of 11

A Study to Compare Standard Chemotherapy to Therapy with CPX-351 and/or Gilteritinib for Patients with Newly Diagnosed AML with or without FLT3 Mutations
Status: Active
Location: 179 locations
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
Status: Active
Location: 24 locations
Venetoclax in Combination with Conventional Chemotherapy for the Treatment of Pediatric Patients with Acute Myeloid Leukemia
Status: Active
Location: 9 locations
Tretinoin and Arsenic Trioxide with or without Gemtuzumab Ozogamicin in Treating Patients with Previously Untreated Acute Promyelocytic Leukemia
Status: Active
Location: 5 locations
Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Patients with Acute Myeloid Leukemia
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients with Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
CPX-351 with Gemtuzumab Ozogamicin for the Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Ziftomenib with Venetoclax and Gemtuzumab Ozogamicin for the Treatment of Pediatric Patients with Relapsed or Refractory Acute Myeloid Leukemia or Mixed Phenotype Acute Leukemia
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Combination Chemotherapy with Gemtuzumab Ozogamicin for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
Status: Enrolling by Invitation
Location: University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland
Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Patients with Blood Cancers
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
MYELOMATCH: A Screening Study to Assign People with Myeloid Cancer to a Treatment Study or Standard of Care Treatment within myeloMATCH (MyeloMATCH Screening Trial)
Status: Active
Location: 301 locations